GlaxoSmithKline plc (the 'Company')
Transaction notification
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
a) |
Name |
Mr Jonathan Symonds |
|||
b) |
Position/status |
Non-Executive Chairman
|
|||
c) |
Initial notification/ amendment |
Initial notification |
|||
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
a) |
Name |
GlaxoSmithKline plc |
|||
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|||
b) |
Nature of the transaction |
Acquisition of notional Ordinary Shares under the share allocation arrangements for Non-Executive Directors for the period of service from 1 July 2019 to 30 September 2019.
|
|||
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
£17.25 |
833.830 |
|
||
|
|
|
|
||
d) |
Aggregated information
|
n/a (single transaction) |
|||
Aggregated volume Price |
|
||||
e) |
Date of the transaction |
2019-10-30 |
|||
f) |
Place of the transaction
|
n/a |
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
a) |
Name |
Mr Vindi Banga |
|||
b) |
Position/status |
Senior Independent Non-Executive Director |
|||
c) |
Initial notification/ amendment |
Initial notification |
|||
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
a) |
Name |
GlaxoSmithKline plc |
|||
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|||
b) |
Nature of the transaction |
Acquisition of notional Ordinary Shares under the share allocation arrangements for Non-Executive Directors for the period of service from 1 July 2019 to 30 September 2019.
|
|||
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
£17.25 |
416.667 |
|
||
|
|
|
|
||
d) |
Aggregated information
|
n/a (single transaction) |
|||
Aggregated volume Price |
|
||||
e) |
Date of the transaction |
2019-10-30 |
|||
f) |
Place of the transaction
|
n/a |
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
a) |
Name |
Dr Vivienne Cox |
|||
b) |
Position/status |
Independent Non-Executive Director |
|||
c) |
Initial notification/ amendment |
Initial notification |
|||
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
a) |
Name |
GlaxoSmithKline plc |
|||
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|||
b) |
Nature of the transaction |
Acquisition of notional Ordinary Shares under the share allocation arrangements for Non-Executive Directors for the period of service from 1 July 2019 to 30 September 2019. |
|||
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
£17.25 |
307.971 |
|
||
|
|
|
|
||
d) |
Aggregated information
|
n/a (single transaction) |
|||
Aggregated volume Price |
|
||||
e) |
Date of the transaction |
2019-10-30 |
|||
f) |
Place of the transaction
|
n/a |
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
a) |
Name |
Ms Lynn Elsenhans |
|||
b) |
Position/status |
Independent Non-Executive Director |
|||
c) |
Initial notification/ amendment |
Initial notification |
|||
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
a) |
Name |
GlaxoSmithKline plc |
|||
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
a) |
Description of the financial instrument |
American Depositary Shares ('ADSs')
ISIN: US37733W1053
|
|||
b) |
Nature of the transaction |
Acquisition of notional ADSs under the share allocation arrangements for Non-Executive Directors for the period of service from 1 July 2019 to 30 September 2019.
|
|||
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
$44.27 |
1,117.592 |
|
||
|
|
|
|
||
d) |
Aggregated information
|
n/a (single transaction) |
|||
Aggregated volume Price |
|
||||
e) |
Date of the transaction |
2019-10-30 |
|||
f) |
Place of the transaction
|
n/a |
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
a) |
Name |
Dr Laurie Glimcher |
|||
b) |
Position/status |
Independent Non-Executive Director |
|||
c) |
Initial notification/ amendment |
Initial notification |
|||
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
a) |
Name |
GlaxoSmithKline plc |
|||
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
a) |
Description of the financial instrument |
American Depositary Shares ('ADSs')
ISIN: US37733W1053
|
|||
b) |
Nature of the transaction |
Acquisition of notional ADSs under the share allocation arrangements for Non-Executive Directors for the period of service from 1 July 2019 to 30 September 2019.
|
|||
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
$44.27 |
1,241.769 |
|
||
|
|
|
|
||
d) |
Aggregated information
|
n/a (single transaction) |
|||
Aggregated volume Price |
|
||||
e) |
Date of the transaction |
2019-10-30 |
|||
f) |
Place of the transaction
|
n/a |
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
a) |
Name |
Dr Jesse Goodman |
|||
b) |
Position/status |
Independent Non-Executive Director |
|||
c) |
Initial notification/ amendment |
Initial notification |
|||
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
a) |
Name |
GlaxoSmithKline plc |
|||
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
a) |
Description of the financial instrument |
American Depositary Shares ('ADSs')
ISIN: US37733W1053
|
|||
b) |
Nature of the transaction |
Acquisition of notional ADSs under the share allocation arrangements for Non-Executive Directors for the period of service from 1 July 2019 to 30 September 2019.
|
|||
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
$44.27 |
374.672 |
|
||
|
|
|
|
||
d) |
Aggregated information
|
n/a (single transaction) |
|||
Aggregated volume Price |
|
||||
e) |
Date of the transaction |
2019-10-30 |
|||
f) |
Place of the transaction
|
n/a |
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
a) |
Name |
Ms Judy Lewent |
|||
b) |
Position/status |
Independent Non-Executive Director |
|||
c) |
Initial notification/ amendment |
Initial notification |
|||
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
a) |
Name |
GlaxoSmithKline plc |
|||
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
a) |
Description of the financial instrument |
American Depositary Shares ('ADSs')
ISIN: US37733W1053
|
|||
b) |
Nature of the transaction |
Acquisition of notional ADSs under the share allocation arrangements for Non-Executive Directors for the period of service from 1 July 2019 to 30 September 2019.
|
|||
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
$44.27 |
417.491 |
|
||
|
|
|
|
||
d) |
Aggregated information
|
n/a (single transaction) |
|||
Aggregated volume Price |
|
||||
e) |
Date of the transaction |
2019-10-30 |
|||
f) |
Place of the transaction
|
n/a |
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
a) |
Name |
Mr Urs Rohner |
|||
b) |
Position/status |
Independent Non-Executive Director |
|||
c) |
Initial notification/ amendment |
Initial notification |
|||
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
a) |
Name |
GlaxoSmithKline plc |
|||
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|||
b) |
Nature of the transaction |
Acquisition of notional Ordinary Shares under the share allocation arrangements for Non-Executive Directors for the period of service from 1 July 2019 to 30 September 2019. |
|||
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
£17.25 |
416.667 |
|
||
|
|
|
|
||
d) |
Aggregated information
|
n/a (single transaction) |
|||
Aggregated volume Price |
|
||||
e) |
Date of the transaction |
2019-10-30 |
|||
f) |
Place of the transaction
|
n/a |